Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry

J Clin Lipidol. 2026 Jul 30:S1933-2874(26)00457-5. doi: 10.1016/j.jacl.2026.07.028. Online ahead of print.ABSTRACTBACKGROUND: Lomitapide is an oral microsomal triglyceride transfer protein inhibitor approved for homozygous familial hypercholesterolemia (HoFH).OBJECTIVE: Evaluate data from the Lomita

D Dirk J Blom

Prophylactic implantation of implantable cardioverter-defibrillator for the primary prevention of sudden cardiac death after myocardial infarction: protocol for systematic review and meta-analysis of randomised controlled trials

BMJ Open. 2026 Aug 18;16(8):e107134. doi: 10.1136/bmjopen-2025-107134.ABSTRACTINTRODUCTION: Cardiovascular disease is a leading cause of death worldwide, of which coronary artery disease is the most common form. Sudden cardiac death (SCD) is a serious complication following acute myocardial infarcti

A Anjalee Thanuja Amarasekera